Case ReportsLevetiracetam May Worsen Myoclonus in Patients With Juvenile Myoclonic Epilepsy: Case ReportsBabtain, Fawzi A. MBBS, FRCP(C)Author Information Neurologist, Epileptologist, Clinical Neurophysiologist, Division of Neurology,Assir Central Hospital, King Khalid University, Abha, Saudi Arabia. Conflicts of Interest and Source of Funding: The author has no conflicts of interest to declare. Address correspondence and reprint requests to Fawzi A. Babtain, MBBS, FRCP(C), Neurologist, Epileptologist, Clinical Neurophysiologist, Division of Neurology, Assir Central Hospital, Assistant Professor of Neurology, College of Medicine, King Khalid University, P O Box 641, Abha, 61421, Saudi Arabia; E-mail: Fawzi.email@example.com Clinical Neuropharmacology: July/August 2012 - Volume 35 - Issue 4 - p 201-202 doi: 10.1097/WNF.0b013e31825eed8c Buy Metrics Abstract Levetiracetam was approved for generalized and partial epilepsy in pediatric and adult population. It is also an effective antimyoclonus, but the evidence only supports its use as an adjunctive agent along with other antiepileptic drugs, such as sodium valproate, and it is commonly used in cases with juvenile myoclonic epilepsy. We report here 2 cases with juvenile myoclonic epilepsy who were switched from sodium valproate to levetiracetam to avoid the cosmetic or future teratogenic effect, but this switch was associated with exaggerated myoclonus despite escalating the dose of levetiracetam but resolved completely after reintroducing sodium valproate. © 2012 Lippincott Williams & Wilkins, Inc.